FDA 执法报告 D-0077-2027 收录 Macleods 奥美沙坦酯/氨氯地平/氢氯噻嗪片两批次溶出度不合格 II 类召回
FDA drug enforcement D-0077-2027: MACLEODS PHARMA USA, INC — Failed Dissolution Specifications.
openFDA 执法报告 D-0077-2027 显示,Macleods Pharma USA 的奥美沙坦酯、氨氯地平与氢氯噻嗪片 40 mg/10 mg/12.5 mg 因溶出度不符合标准被定为 II 类召回,由企业主动发起。
FDA drug recall enforcement report — D-0077-2027
Report issued: 2026-11-04. This is the enforcement report date, not the recall initiation date.
Scope: one classified drug product recall record; event_id may group multiple products. Unclassified records without recall numbers are outside this stream. This record is not a press release or a new enforcement finding.
The openFDA dataset is updated weekly. Report status is not a live recall status and must not be used to track the recall lifecycle. Other dates below retain their named meanings.
Complete official product record (including openFDA harmonized identifiers):
{
"address_1": "103 College Rd E Fl 2",
"address_2": "",
"center_classification_date": "20261026",
"city": "Princeton",
"classification": "Class II",
"code_info": "Lot #: a) 12251163A, Exp 05-31-2027; b) 12251163B, Exp 05-31-2027",
"country": "United States",
"distribution_pattern": "Nationwide in the USA",
"event_id": "100113",
"initial_firm_notification": "Letter",
"more_code_info": "",
"openfda": {
"application_number": [
"ANDA207088"
],
"brand_name": [
"OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE"
],
"generic_name": [
"OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE"
],
"is_original_packager": [
true
],
"manufacturer_name": [
"Macleods Pharmaceuticals Limited"
],
"nui": [
"N0000175359",
"N0000175419",
"M0471776"
],
"package_ndc": [
"33342-243-07",
"33342-243-10",
"33342-244-07",
"33342-244-10",
"33342-245-07",
"33342-245-10",
"33342-246-07",
"33342-246-10",
"33342-247-07",
"33342-247-10"
],
"pharm_class_cs": [
"Thiazides [CS]"
],
"pharm_class_epc": [
"Thiazide Diuretic [EPC]"
],
"pharm_class_pe": [
"Increased Diuresis [PE]"
],
"product_ndc": [
"33342-243",
"33342-244",
"33342-245",
"33342-246",
"33342-247"
],
"product_type": [
"HUMAN PRESCRIPTION DRUG"
],
"route": [
"ORAL"
],
"rxcui": [
"999967",
"999986",
"999991",
"999996",
"1000001"
],
"spl_id": [
"52c013e1-8c31-4bed-9241-e7845873ebe8"
],
"spl_set_id": [
"52c013e1-8c31-4bed-9241-e7845873ebe8"
],
"substance_name": [
"OLMESARTAN MEDOXOMIL",
"AMLODIPINE BESYLATE",
"HYDROCHLOROTHIAZIDE"
],
"unii": [
"6M97XTV3HD",
"0J48LPH2TH",
"864V2Q084H"
],
"upc": [
"0333342247070",
"0333342245076"
]
},
"postal_code": "08540-6611",
"product_description": "Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets 40 mg/10 mg/12.5mg, packaged as a) 30-count bottle, NDC 33342-246-07; b) 90-count bottle, NDC 33342-246-10; Rx Only, Manufactured for : Macleods Pharma USA, Inc. Princeton, NJ 08540, Manufactured by: Macleods Pharmaceuticals Ltd, Daman, 396210, India",
"product_quantity": "3528 30-count and 216 90-count bottles",
"product_type": "Drugs",
"reason_for_recall": "Failed Dissolution Specifications.",
"recall_initiation_date": "20261007",
"recall_number": "D-0077-2027",
"recalling_firm": "MACLEODS PHARMA USA, INC",
"report_date": "20261104",
"state": "NJ",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov